Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics
GET POWR RATINGS... FREE!
XENE POWR Grades
- XENE scores best on the Value dimension, with a Value rank ahead of 45.52% of US stocks.
- XENE's strongest trending metric is Growth; it's been moving down over the last 177 days.
- XENE ranks lowest in Growth; there it ranks in the 5th percentile.
XENE Stock Summary
- With a price/sales ratio of 184.39, XENON PHARMACEUTICALS INC has a higher such ratio than 98.4% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.03 for XENON PHARMACEUTICALS INC; that's greater than it is for just 6.4% of US stocks.
- As for revenue growth, note that XENE's revenue has grown -33.65% over the past 12 months; that beats the revenue growth of merely 5.86% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to XENON PHARMACEUTICALS INC are MRUS, AFMD, RAPT, TSVT, and FGEN.
- Visit XENE's SEC page to see the company's official filings. To visit the company's web site, go to www.xenon-pharma.com.
XENE Valuation Summary
- XENE's price/sales ratio is 184.7; this is 9135% higher than that of the median Healthcare stock.
- XENE's EV/EBIT ratio has moved down 29.8 over the prior 98 months.
Below are key valuation metrics over time for XENE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XENE | 2022-12-02 | 184.7 | 3.2 | -21.6 | -20.5 |
| XENE | 2022-12-01 | 175.4 | 3.1 | -20.5 | -19.4 |
| XENE | 2022-11-30 | 175.1 | 3.1 | -20.5 | -19.4 |
| XENE | 2022-11-29 | 172.8 | 3.0 | -20.2 | -19.1 |
| XENE | 2022-11-28 | 173.2 | 3.0 | -20.2 | -19.2 |
| XENE | 2022-11-25 | 165.3 | 2.9 | -19.3 | -18.2 |
XENE Growth Metrics
- Its 5 year price growth rate is now at 66.11%.
- The 4 year price growth rate now stands at 66.11%.
- Its 3 year net cashflow from operations growth rate is now at -91.12%.
The table below shows XENE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 13.171 | -86.408 | -112.756 |
| 2022-06-30 | 21.163 | -71.013 | -90.689 |
| 2022-03-31 | 22.845 | -67.222 | -81.119 |
| 2021-12-31 | 18.437 | -69.502 | -77.087 |
| 2021-09-30 | 19.85 | -61.906 | -63.985 |
| 2021-06-30 | 18.28 | -58.053 | -57.507 |
XENE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XENE has a Quality Grade of D, ranking ahead of 7.55% of graded US stocks.
- XENE's asset turnover comes in at 0.077 -- ranking 283rd of 681 Pharmaceutical Products stocks.
- ADMP, ACUR, and ELTP are the stocks whose asset turnover ratios are most correlated with XENE.
The table below shows XENE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.077 | 1 | -0.353 |
| 2021-03-31 | 0.132 | 1 | -0.233 |
| 2020-12-31 | 0.154 | 1 | -0.194 |
| 2020-09-30 | 0.153 | 1 | -0.197 |
| 2020-06-30 | 0.157 | 1 | -0.237 |
| 2020-03-31 | 0.094 | 1 | -0.381 |
XENE Price Target
For more insight on analysts targets of XENE, see our XENE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.88 | Average Broker Recommendation | 1.17 (Strong Buy) |
XENE Stock Price Chart Interactive Chart >
XENE Price/Volume Stats
| Current price | $38.83 | 52-week high | $41.39 |
| Prev. close | $38.89 | 52-week low | $23.26 |
| Day low | $38.35 | Volume | 254,400 |
| Day high | $39.30 | Avg. volume | 448,612 |
| 50-day MA | $35.77 | Dividend yield | N/A |
| 200-day MA | $33.33 | Market Cap | 2.43B |
Xenon Pharmaceuticals Inc. (XENE) Company Bio
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.
Latest XENE News From Around the Web
Below are the latest news stories about XENON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XENE as an investment opportunity.
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)Company Presents Additional Positive Data from Open Label Extension of Phase 2b ‘X-TOLE’ Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022 BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American E |
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022. Fireside Chat/Company Presentation Details: Date:Wednesday, December 7, 2022Time:1:10 pm Eastern Time (10:10 am Pacific T |
Xenon Pharmaceuticals Stock Scores Rising Relative Strength UpgradeXenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday. Is Xenon Pharmaceuticals Stock A Buy? Xenon Pharmaceuticals stock is building a consolidation with a 41.49 entry. |
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts By 10%Market forces rained on the parade of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) shareholders today, when the analysts... |
Xenon Pharmaceuticals to Participate in Upcoming Investor ConferencesBURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will host fireside chat presentations and participate in one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology Day on Monday, November 14, 2022 with a firesid |
XENE Price Returns
| 1-mo | 8.77% |
| 3-mo | 3.22% |
| 6-mo | 30.83% |
| 1-year | 57.02% |
| 3-year | 178.35% |
| 5-year | 1,552.34% |
| YTD | 24.30% |
| 2021 | 103.12% |
| 2020 | 17.32% |
| 2019 | 107.77% |
| 2018 | 123.36% |
| 2017 | -63.31% |
Loading social stream, please wait...